Aptose Biosciences (APTO) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APTO shares.
View APTO analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12 month price objectives for Aptose Biosciences' shares. Their APTO share price forecasts range from $5.00 to $8.00. On average, they predict the company's stock price to reach $6.33 in the next year. This suggests a possible upside of 1,384.6% from the stock's current price.
View analysts price targets for APTO or view top-rated stocks among Wall Street analysts.

Aptose Biosciences' stock was trading at $0.58 at the beginning of 2023. Since then, APTO stock has decreased by 26.4% and is now trading at $0.4266.
View the best growth stocks for 2023 here.

Aptose Biosciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 264,100 shares, an increase of 44.6% from the April 30th total of 182,700 shares. Based on an average daily trading volume, of 181,600 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.3% of the company's stock are sold short.
View Aptose Biosciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our APTO earnings forecast.

Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings data on Thursday, March, 23rd. The biotechnology company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). During the same quarter last year, the company posted ($0.27) earnings per share.

8 employees have rated Aptose Biosciences Chief Executive Officer William G. Rice, Ph.D. on Glassdoor.com. William G. Rice, Ph.D. has an approval rating of 34% among the company's employees. This puts William G. Rice, Ph.D. in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 52.0% of employees surveyed would recommend working at Aptose Biosciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Arch Therapeutics (ARTH), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Anavex Life Sciences (AVXL), CymaBay Therapeutics (CBAY), Cisco Systems (CSCO), Micron Technology (MU) and SCYNEXIS (SCYX).

Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO."

Aptose Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Sigma Planning Corp (1.56%), Renaissance Technologies LLC (0.35%) and Two Sigma Advisers LP (0.08%). Insiders that own company stock include Denis R Burger, Donald R Jr Wilson, Erich Platzer, Gregory K Chow, Jotin Marango, Rafael Bejar, Warren Whitehead and William G Rice.
View institutional ownership trends.

Shares of APTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of APTO stock can currently be purchased for approximately $0.43.

Aptose Biosciences (NASDAQ:APTO) has a market capitalization of $39.65 million. The biotechnology company earns $-41,820,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

Aptose Biosciences' mailing address is 251 CONSUMERS ROAD SUITE 1105, TORONTO A6, M2J 4R3. The official website for the company is www.aptose.com. The biotechnology company can be reached via phone at 858-926-2730, via email at ir@aptose.com, or via fax at 905-234-2120.